CSTL CASTLE BIOSCIENCES INC

CIK 0001447362 50 ready 8-Ks latest July 30, 2026, 4:06 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 50

Latest filing July 30, 2026, 4:06 PM ET

Top materiality 0.85

Event mix earnings ×26 · other_material ×10 · other ×7

Sentiment 25 pos · 3 neg · 22 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CSTL

Highest-materiality recent filing

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

August 5, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.

Read filing →

July 30, 2026, 4:06 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M

Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.
May 29, 2026, 4:14 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

Castle Biosciences stockholders elect three Class I directors and ratify KPMG as auditor at 2026 annual meeting

Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson elected as Class I directors to serve until 2029 annual meeting.
May 6, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M

Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).
February 26, 2026, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024

FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
January 13, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY

2025 total revenue >$340M, above guided range of $327-335M.
November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test

Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
August 8, 2025, 7:59 PM ET other material materiality 0.25 neutral item 5.03 item 9.01 ◈ Governance Changes

Castle Biosciences adopts amended bylaws with changes to meeting procedures and governance

Board adopted amended and restated bylaws effective August 5, 2025, modifying quorum, advance notice, and proxy rules.
August 4, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY

Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
May 23, 2025, 7:59 PM ET other material materiality 0.35 neutral item 3.03 item 5.03 item 5.07 item 9.01 ◈ Governance Changes

Castle Biosciences shareholders approve officer exculpation charter amendment; re-elect directors

Stockholders approved amendment to certificate of incorporation to limit officer liability per Delaware law, effective May 22, 2025.
May 5, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 7.01 item 9.01

Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse

Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M

Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC

Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.
November 4, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q3 revenue up 39% to $85.8M; raises FY2024 guidance to $320-330M

Revenue $85.8M (+39% YoY); net income $2.3M vs. ($6.9M) loss; adj. EBITDA $21.6M vs $6.6M.
August 5, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
May 24, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Castle Biosciences stockholders elect directors, ratify KPMG, approve say-on-pay at 2024 annual meeting

Daniel M. Bradbury elected as Class II director with 15.95M for, 5.28M withhold; Rodney Cotton with 21.11M for, 117K withhold.
May 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M

Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).
March 27, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 5.02 item 9.01 ◈ executive_change ×2◈ Material Agreements

Castle Biosciences secures $35M SVB loan facility; appoints Rodney Cotton to board

Entered Loan Agreement with Silicon Valley Bank for $10M drawn, $25M additional available.
February 28, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences FY2023 revenue $219.8M (+60%); Q4 $66.1M; guides 2024 $235-240M

Full-year 2023 revenue $219.8M (+60% YoY); total test reports 70,429 (+59%). Q4 revenue $66.1M (+72% YoY).
January 8, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%

Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.
November 9, 2023, 6:59 PM ET other material materiality 0.50 neutral item 5.02

Castle Biosciences adopts Severance and Change in Control Plan for top executives

Plan adopted Nov 3, 2023; covers CEO Maetzold, CFO Stokes, CCO Juvenal, COO Oelschlager.
November 2, 2023, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M

Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.
August 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M

Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).
June 5, 2023, 7:59 PM ET other materiality 0.35 neutral item 7.01

Castle Biosciences reaffirms FY2023 revenue guidance of $170-180M and 2025 targets

Reaffirms FY2023 total revenue guidance of $170-$180M.
June 1, 2023, 7:59 PM ET other materiality 0.15 negative item 5.07

Castle Biosciences shareholders reject say-on-pay at 2023 annual meeting

Advisory vote on named executive officer compensation failed: 8.96M for, 11.10M against, 41.7K abstain, 1.73M broker non-votes.
May 3, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences Q1 revenue up 57% to $42M; reaffirms FY 2023 guidance $170-180M

Delivered 14,916 total test reports (+73% YoY); DecisionDx-Melanoma 7,583 (+26%), DecisionDx-SCC 2,411 (+111%).
February 28, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Castle Biosciences FY2022 revenue $137M (+46% YoY); guides FY2023 revenue $170-180M

Full-year 2022 revenue $137.0M, up 46% from $94.1M; test reports 44,419, up 58%.
January 20, 2023, 6:59 PM ET other materiality 0.25 neutral item 5.02

Castle Biosciences adopts retirement policy accelerating equity vesting for eligible employees

Policy covers VP-level and above employees retiring after age 60 with 5+ years of service.
January 9, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance

Total test reports in 2022: 44,338, up 58% YoY from 28,118.
December 28, 2022, 6:59 PM ET other materiality 0.25 neutral item 5.02

Castle Biosciences adopts 2022 Inducement Plan for 350,000 shares to attract new employees

Board approved 2022 Inducement Plan reserving 350,000 shares of common stock for new hires as material inducement.
December 15, 2022, 6:59 PM ET other material materiality 0.40 neutral item 5.02

Castle Biosciences grants time-based and performance-based RSUs to CEO, CFO, CCO, COO

Grant of 133,983 time-based and 133,982 performance-based RSUs to CEO Derek J. Maetzold.
November 2, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M

Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).
August 8, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M

Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.
June 8, 2022, 7:59 PM ET other material materiality 0.15 negative item 5.07

Stockholders reject advisory say-on-pay proposal at Castle Biosciences annual meeting

Say-on-pay failed: 8,331,458 For vs 11,985,739 Against; broker non-votes 1,869,015.
June 3, 2022, 7:59 PM ET other material materiality 0.25 neutral item 8.01 item 9.01

Castle Biosciences files updated pro forma financials for Cernostics acquisition

Pro forma net loss of $38.9M for FY2021, including $3.6M in transaction accounting adjustments.
May 9, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance

Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.
May 2, 2022, 7:59 PM ET M&A materiality 0.70 neutral item 3.02

Castle Biosciences completes AltheaDx acquisition; issues 763,887 shares

$65M initial consideration: $32.5M cash and $32.5M in stock (763,887 shares).
April 7, 2022, 7:59 PM ET other material materiality 0.55 neutral item 1.01

Castle Biosciences signs 126-month lease for 44,677 sq ft Pittsburgh office/lab

Initial term of 126 months; first 36 months 20,856 sq ft, expanding to 44,677 sq ft from month 37.
April 4, 2022, 7:59 PM ET M&A materiality 0.70 neutral item 1.01 item 3.02 item 9.01

Castle Biosciences to acquire AltheaDx for $65M upfront plus up to $75M in milestones

Upfront consideration: $32.5M cash + $32.5M stock; milestone payments up to $75M tied to 2022-2024 revenue and Medicare coverage.
March 17, 2022, 7:59 PM ET other material materiality 0.30 neutral item 1.01 item 9.01

Castle Biosciences expands Phoenix office by 5,904 sq ft, extends lease through 2033

Expanded premises include Suite 170, adding 5,904 rentable sq ft for total ~17,820 sq ft.
February 28, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M

Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.
January 14, 2022, 6:59 PM ET M&A materiality 0.60 positive item 9.01

Castle Biosciences acquires Cernostics for up to $30M upfront plus $50M earnout

Up-front consideration $30M (cash or cash/stock mix); earnouts up to $50M based on 2022 commercial milestones.
January 10, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%

FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.
January 5, 2022, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Castle Biosciences Chief Business Officer resigns; enters consulting agreement with vesting extension

Bernhard Spiess resigns as CBO effective Dec 31, 2021; separation agreement signed Dec 29, 2021.
December 6, 2021, 6:59 PM ET M&A materiality 0.60 neutral item 1.01 item 2.01 item 9.01

Castle Biosciences completes acquisition of Cernostics for $30M upfront cash, up to $50M earnout

Acquisition closed December 3, 2021; upfront cash consideration approximately $30 million.
December 3, 2021, 6:59 PM ET other material materiality 0.35 neutral item 1.01 item 9.01

Castle Biosciences extends Phoenix office leases through April 2033, adds 2,564 sq ft

3707 Lease amended: term extended 61 months to April 2033; premises expanded by 2,564 sq ft to 17,752 total.
November 8, 2021, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Castle Q3 revenue $23.5M (+54% YoY); guides FY21 $89-93M; acquiring Cernostics

Q3 revenue $23.5M, up 54% vs $15.2M in Q3 2020; adjusted revenue $23.6M, up 71%.
October 19, 2021, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 7.01 item 8.01 item 9.01

Castle Biosciences to acquire Cernostics for up to $80M; expands into GI diagnostics with TissueCypher

Upfront consideration of $30M (cash or $20M cash + $10M stock at Castle's discretion); up to $50M in milestones based on 2022 performance.
September 9, 2021, 7:59 PM ET other materiality 0.10 neutral item 8.01 item 9.01

Castle Biosciences presents at Wells Fargo Healthcare Conference with slide deck

Castle Biosciences presented at the 2021 Virtual Wells Fargo Healthcare Conference on September 9, 2021.
August 9, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Castle Biosciences Q2 revenue $22.8M (+79% YoY); raises FY2021 guidance to $89-93M

Revenue $22.8M, up 79% YoY; adjusted revenue $22.9M, up 120% YoY excluding prior-period adjustments.
July 16, 2021, 7:59 PM ET leadership materiality 0.20 neutral item 5.02 ◈ executive_change ×2

Castle Biosciences appoints Kimberlee Caple and Ellen Goldberg to board

Appointed Kimberlee Caple as Class III director (term until 2022 annual meeting).

Executive changes

Departed

Mara G. Aspinall

Director

CSTL · CASTLE BIOSCIENCES INC

Filed: March 27, 2024, 7:59 PM ET

On March 26, 2024, Mara G. Aspinall notified the Company that she will not to stand for re-election to the board of directors (the “Board”) of the Company at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).

Appointed

Rodney Cotton

Class II Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2024-03-26
Filed: March 27, 2024, 7:59 PM ET

On March 26, 2024, following the recommendation of the nominating and corporate governance committee of the Board, the Board increased the size of the Board from eight to nine members and appointed Rodney Cotton to serve as a Class II director with a term ending at the 2024 Annual Meeting.

Departed

Bernhard E. Spiess

Chief Business Officer

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-12-31
Filed: January 5, 2022, 6:59 PM ET

Bernhard E. Spiess, former Chief Business Officer of Castle Biosciences, Inc. (the “Company”), notified the Company of his intention to resign effective as of December 31, 2021.

Appointed

Kimberlee Caple

Class III Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-07-14
Filed: July 16, 2021, 7:59 PM ET

the Board appointed (i) Kimberlee Caple to serve as a Class III director until the Company’s 2022 annual meeting of stockholders

Appointed

Ellen Goldberg

Class I Director

CSTL · CASTLE BIOSCIENCES INC

Effective: 2021-07-14
Filed: July 16, 2021, 7:59 PM ET

and (ii) Ellen Goldberg to serve as a Class I director until the Company’s 2023 annual meeting of stockholders

Earnings & guidance

2026-Q1 EPS reported -$0.49 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

25 positive 3 negative 22 neutral

source · CSTL on sec.gov